News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

VaxGen, Inc. (VXGN) and Kaketsuken End Smallpox Vaccine Partnership

6/11/2007 12:06:32 PM

SOUTH SAN FRANCISCO, Calif., June 11 /PRNewswire-FirstCall/ -- VaxGen, Inc. and the Chemo-Sero Therapeutic Research Institute (Kaketsuken) of Japan announced today that they have terminated by mutual consent their agreement to co-develop a next-generation, attenuated smallpox vaccine, LC16m8, for use in the United States and elsewhere.


"We continue to believe that this vaccine represents a significant advance over traditional, non-attenuated smallpox vaccines," said James P. Panek, VaxGen's President and CEO. "However, VaxGen was left with no choice but to discontinue development of the vaccine given the lack of a commitment from the U.S. government to fund its development or purchase, and our decision to discontinue biodefense activities. We are hopeful that Kaketsuken will be able to carry on the development of LC16m8 and ultimately make it available to the American people."

Under the terms of the termination agreement, VaxGen will transfer to Kaketsuken or its designee all reports, data and materials and all intellectual property rights that relate to conducting non-clinical and clinical development of LC16m8 in the U.S. In return, Kaketsuken has released VaxGen from ongoing development obligations.

LC16m8 was initially developed in Japan to address the need for an attenuated smallpox vaccine that was as effective, but safer than conventional, unattenuated smallpox vaccines. Studies involving approximately 90,000 children were conducted in Japan, where LC16m8 is currently approved and manufactured commercially. LC16m8 is a cloned virus vaccine produced in cell culture that has been shown to be less neurovirulent than unattenuated strains of vaccinia vaccines in preclinical models.

About VaxGen

VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases. For more information, please visit the company's web site at

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the termination of VaxGen's agreement with Kaketsuken and possible future development of LC16m8 by Kaketsuken. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Photo: NewsCom: Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comVaxGen, Inc.

CONTACT: Lance Ignon, Vice President, Corporate Affairs of VaxGen, Inc.,+1-650-624-1016

Read at

comments powered by Disqus